Main Menu

HIV microbicides are not currently sold commercially, and many other HIV prevention techniques remain unavailable or unfeasible in developing countries where the disease is most prevalent. The technology transfer effort of developing large scale production methods of CV-N in soy beans helps to address this issue. The ability to produce CV-N in large quantities at low cost affords researchers the potential to develop effective HIV prevention methods worldwide.
 

HIV microbicides are not currently sold commercially, and many other HIV prevention techniques remain unavailable or unfeasible in developing countries where the disease is most prevalent. The technology transfer effort of developing large scale production methods of CV-N in soy beans helps to address this issue. The ability to produce CV-N in large quantities at low cost affords researchers the potential to develop effective HIV prevention methods worldwide.
 

Through a CRADA with EMD Serono, NCI played an instrumental role in developing and 
expediting regulatory approval of EMD Serono’s checkpoint inhibitor, avelumab. Avelumab 
received FDA approval in 2017, only four years after EMD Serono and NCI added the study of 
avelumab to their CRADA. This was a remarkably fast developmental and regulatory approval 
timeline.

Through a CRADA with EMD Serono, NCI played an instrumental role in developing and 
expediting regulatory approval of EMD Serono’s checkpoint inhibitor, avelumab. Avelumab 
received FDA approval in 2017, only four years after EMD Serono and NCI added the study of 
avelumab to their CRADA. This was a remarkably fast developmental and regulatory approval 
timeline.

Sidra Ahsan, Ph.D., a fellow at the NCI TTC, received the “Rookie

NCI received the “Educational Institution and Federal Laboratory Partnership Award” at the Federal Laboratory Consortium 2018 Mid-Atlantic meeting for the establishment of the “NCI Immunotherapy Fellowship Co-sponsored by Society for Immunotherapy of Cancer.” “The award exemplifies what is possible through engaged partnerships, in this case, TTC, investigators from NCI’s Center for Cancer Research, a CRADA partner and a non-profit,” commented Dr.

The Foundation for the National Institutes of Health (FNIH) besto

In 2011, NCI and Iovance Biotherapeutics entered into a CRADA for the development of Adoptive Cell Therapy (ACT) using Tumor Infiltrating Lymphocytes (TIL). Technology licenses between NCI and Iovance were established to grant Iovance rights to the NIH’s TIL patent estate. By 2019, Iovance began conducting two pivotal multi-center trials of TIL technology in advanced cervical cancer and metastatic melanoma and has achieved Breakthrough Therapy and Fast Track designations from the FDA in these indications, respectively.

In September 2016, to better engage and educate the scientific community, the NCI TTC launched the first federal Technology Transfer Ambassadors Program (TTAP). The program has significantly impacted TT efforts at the NCI and is now being offered across the NIH. TTAP is the first formal TT training and mentoring program open to NIH post-doctoral (post-docs) scientists and staff scientists/staff clinicians seeking professional development in invention analysis, commercialization, and entrepreneurship.

The National Cancer Institute’s (NCI) Technology Transfer Center (TTC) has taken home a State and Local Economic Development award from the 2021 Federal Laboratory Consortium (FLC) awards. The NCI TTC started a yearly event in 2017 with the Frederick National Laboratory (FNL) to highlight technologies and inventions available for licensing and collaboration. Hosting the event at FNL allowed everyone to take advantage of the regional resources and relationships that the City and County of Frederick have.